Starting Wegovy at 1.7mg: what to expect from that dose

You've been told (or you've read) that 1.7mg is on the schedule. Here's the context that changes everything.

Picture someone handed a prescription that reads 1.7mg, either because a previous provider started there, because a dose was skipped, or because they found the information somewhere online and are wondering whether it's safe to begin there. It is a reasonable question, and the answer sits inside how semaglutide works.

Semaglutide acts on GLP-1 receptors in the gut and brain, slowing how quickly the stomach empties and reducing appetite signals. Those effects intensify as the dose climbs. At 0.25mg the body's exposure is relatively modest. At 1.7mg, a dose that sits one rung below the full 2.4mg maintenance level, the pharmacological effect is considerably stronger. The NHS medicines page for semaglutide confirms the graduated titration: 0.25mg, then 0.5mg, then 1.0mg, then 1.7mg, before reaching 2.4mg, each step allowing the gastrointestinal tract time to settle before the next increase.

Beginning at 1.7mg compresses that adaptation window to zero. The stomach-emptying effect arrives at full force before the body has learned to buffer it. That is not a small technical detail; it is the main reason the schedule is structured the way it is. For more context on where each dose sits in the overall picture, the Wegovy doses guide covers the full escalation pathway in plain terms.

The side effects that cluster around higher doses, and why earlier rungs reduce them

Nausea is the most commonly reported side effect with semaglutide. So are vomiting, diarrhoea, constipation and reflux. In the STEP 1 clinical trial, published in the New England Journal of Medicine, gastrointestinal events were the most frequent reason participants experienced discomfort, and they were notably more concentrated around dose increases than at steady state. That is the mechanism the titration schedule is designed to exploit in your favour: each step up is a small enough jump that the GI tract can adjust before the next one arrives.

Starting at 1.7mg removes every one of those adaptation buffers. Nausea that would normally arrive gently at 0.25mg and fade before the 0.5mg step arrives instead hits at full intensity. For some people the result is manageable. For others it leads to early discontinuation, which means less of the intended clinical benefit, not more. Fatigue and headache can also be more pronounced. None of these are reasons to panic, but they are reasons the schedule exists. If you have already started at a higher dose and things feel difficult, your prescriber is the right person to talk to about whether slowing the pace or stepping back is appropriate. It is also worth knowing that accidentally taking two doses is a related risk when schedules are disrupted, and the guide on what happens if you take 2 doses of Wegovy explains what to expect and what to do. Missing doses mid-treatment is a separate but related issue, and the guide on missed Wegovy doses explains what to do if that happens.

It is worth being clear that side effects at any dose are not inevitable. Some people tolerate even the higher steps without significant trouble. The point is that the risk of a difficult reaction is higher when the usual build-up has been bypassed.

What 2.4mg actually does that 1.7mg does not, and where your dose ends up

The 1.7mg step is real and licensed, but it is transitional. The 2.4mg dose is where the weight-management licence's clinical evidence is strongest, the STEP 1 trial showing around 15% average body weight reduction over 68 weeks was conducted at 2.4mg maintenance, not 1.7mg. Starting at 1.7mg might feel like getting ahead, but it still leaves one dose increase to navigate, and that increase carries its own side-effect risk, particularly if the earlier groundwork was skipped.

There is also a practical timing consideration. People sometimes ask about dose changes when they have a holiday coming up, a busy week at work, or they are trying to align injections with a payday order. Those are real-life concerns, and it is fine to raise them with your prescriber. What is not fine is unilaterally starting at a higher dose because it seems more efficient. The prescriber reviewing your case has access to your full health picture; you do not have theirs.

For comparison, the page on starting at 1.0mg covers that mid-schedule step in detail if that is closer to your situation. If you are already on 2.4mg and wondering what reaching that dose actually means for results, the 2.4mg guide gives the full picture.

What your prescriber needs to know before any dose decision

Prescribers assessing Wegovy eligibility and dosing consider more than a single BMI number. Past GI conditions, current medications, tolerance of previous doses, and whether any weight-related health conditions are present all feed into the clinical picture. The Wegovy SmPC is the definitive clinical reference; the broader context of how the treatment is assessed in the UK is covered well on NHS England's weight management injections guidance.

If someone else has already started you at 1.7mg and you are wondering whether that was appropriate, the honest answer is: it depends on your individual clinical history, and only your prescriber can assess that. If you are considering treatment from scratch and wondering whether to negotiate a faster start, the short answer is that a good prescriber will not agree to it without a clinical reason, and that is a sign of a good prescriber, not a barrier.

Cost is sometimes part of the thinking here. Some people assume skipping doses reduces overall spend. Whether that stacks up is worth reading through on the Wegovy cost page, which also covers what a transparent private prescription actually includes. Treatment from a GPhC-registered service means every dose change is reviewed by a real clinician, not processed automatically. At nume, a prescriber personally reviews your case before anything is dispensed. If you would like that assessment, you can start your free consultation at any point.